MedPath

Krachttraining en eiwitsuppletie ter preventie van bijwerkingen van hormonale behandeling bij mannen met prostaatkanker.

Recruiting
Conditions
prostate cancer, androgen deprivation therapy, muscle mass, resistance exercise, protein supplementationprostaatkanker, androgen deprivatie therapie, spiermassa, krachtttraining, eiwitsuppletie
Registration Number
NL-OMON20332
Lead Sponsor
Maastricht University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
208
Inclusion Criteria

Men with PC on ADT for progressive disease (metastatic disease or increasing PSA level after primary treatment)

Exclusion Criteria

- Allergies to whey protein

- Lactose intolerance

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Body composition: body weight, body height, BMI, waist circumference, muscle mass, fat mass, body fat distribution assessed with DEXA and quadriceps muscle cross-sectional area measured by CT scanning of the upper leg.
Secondary Outcome Measures
NameTimeMethod
Muscle strength: measured by 1-RM<br /><br>„h Maximal oxygen uptake (VO2max)<br /><br>„h Physical performance (timed Up and Go test, 30 seconds chair stand test, stair climbing test)<br /><br>„h Level of independent living (The Impact on Participation and Autonomy (IPA) Questionnaire) (Appendix F1.2)<br /><br>„h HRQoL (EORTC QLQ-C30, EORTC QLQ-PR25) (Appendix F1.3 en F1.4)<br /><br>„h Fatigue (Multidimensional Fatigue Inventory (MFI) (Appendix F1.5)<br /><br>„h Blood results (PSA, testosterone, LDH, alkalis phosphatase, triglycerides, cholesterol (HLD, LDL and total), glucose, creatinine, liver function)<br /><br>„h Adverse events (Number, kind and seriousness)
© Copyright 2025. All Rights Reserved by MedPath